Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Nov 15, 2022 7:03pm
159 Views
Post# 35101626

RE:RE:RE:RE:RE:Roche experiences second failure in Alzheimer's disease

RE:RE:RE:RE:RE:Roche experiences second failure in Alzheimer's diseaseNoteable... you have bombarded this bb with hopium about a buyout... for how many years now... I think at least 3.. and what has the PPS done in that time..?

I have only been on this board for just over 1 year and began to speculate on ONCY's potential acquisition about 4 months ago . Until then I posted on the worth of a company with the kind of assets that ONCY has to offer as a "bolt-on" acquisition.

What about Matt's reference to a "partnership" you ask? - well .... talk of a partnership is how talks begins but as interests are shared those talks quickly move to talk around an acquistion, particularly when there are a number of Big Pharma companies who've  "come-a-calling". This is now happening at a time when there is significant competition for immuno-oncology assets since Big Pharma faces a looming patent cliff and a need to add products to their oncology franchises.


<< Previous
Bullboard Posts
Next >>